Makale detayı · 2026 · article
Serum FGF-23 and Sclerostin Levels in Hemodialysis Patients: Associations with Bone Mineral Density and Fracture Risk
Veri kaynağı ayrımı
- YÖKSİSYÖKSİS makale kaydı
- YÖKSİS dergi adıSağlık Bilimlerinde Değer
- OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
- Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)
Özet
Aim: This study aimed to evaluate serum fibroblast growth factor-23 (FGF-23) and sclerostin levels in hemodialysis patients compared with healthy controls, and to investigate their associations with bone mineral density (BMD) and fracture risk.. Material and methods: A total of 66 participants were included: 40 patients undergoing maintenance hemodialysis and 26 age- and sex-matched healthy controls. Demographic, clinical, and biochemical parameters were recorded. Serum FGF-23 and sclerostin were measured using ELISA. BMD was assessed at the lumbar spine and femoral neck using DXA, and fracture risk was estimated using FRAX scores. In addition to correlation and multivariate regression analyses, between-group comparisons were performed using appropriate statistical tests, and categorical variables were evaluated with chi-square analysis. Results: Hemodialysis patients had significantly higher serum FGF-23 (p<0.001) and sclerostin (p<0.001) levels compared with controls. Lumbar spine and femoral BMD values were significantly lower in the hemodialysis group (p=0.004 and p=0.006, respectively), while FRAX major osteoporotic and hip fracture risk scores were significantly higher (p=0.002 and p=0.001, respectively). FGF-23 and sclerostin showed positive correlations with phosphate (p=0.002 and p=0.004) and PTH (p=0.01 and p=0.009), and negative correlations with lumbar BMD (p=0.01 and p=0.008). In multivariate regression, phosphate (p=0.01) and PTH (p=0.008) were independent determinants of FGF-23, while phosphate (p=0.02) and lumbar BMD (p=0.01) were independent determinants of sclerostin. Conclusion: Elevated FGF-23 and sclerostin levels, along with reduced BMD and increased fracture risk, characterize hemodialysis patients. These biomarkers may complement densitometric measures in evaluating bone fragility in chronic kidney disease.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
0atıfOpenAlex · cited_by_count (önbellek / veritabanı)